Plasmagen Biosciences Appoints Vivek V Kamath as Chief Exective Officer

Plasmagen Biosciences (‘Plasmagen’), a biopharmaceutical company focused on blood plasma-derived pharmaceutical products for India and emerging markets, today announced the appointment of Vivek V Kamath as its Chief Executive Officer, with effect from 6th October, 2025.

Vivek brings over three decades of leadership experience in healthcare, spanning pharmaceuticals, over-the-counter (OTC) products and diagnostics. His experience extends across geographies like India, South Asia and Southeast Asia where he has held senior leadership roles, including serving as the Managing Director of Abbott India Ltd., Abbott Healthcare Ltd., and MSD Pharmaceuticals (South Asia). Vivek has also been a strategic advisor to leading private equity funds, supporting the growth of their healthcare portfolio companies.

“Plasmagen’s mission is to become a trusted and leading Indian biopharmaceutical company that improves the health and quality of life of patients globally. Vivek’s deep experience in leading large organizations, coupled with his operational expertise and ability to build world-class teams, makes him an outstanding addition to our leadership team” said Vinod Nahar,
Founder and Executive Chairman, Plasmagen Biosciences. “With Vivek’s appointment as CEO, I will step into the Executive Chairman role steering Plasmagen’s long-term strategy. I look
forward to working alongside him as we build India’s premier fully integrated plasma products company.”

The company’s best-in-class manufacturing facility commenced commercial operations in 2024, positioning Plasmagen for rapid growth as the only end-to-end, pure play plasma products company in South Asia. The company is now well positioned to expand beyond India as it aims to make its portfolio of life-saving medicines available to patients worldwide.

Commenting on his appointment, Vivek V Kamath, CEO, Plasmagen Biosciences said: “Plasmagen’s combination of world-class manufacturing and a purpose-driven leadership team has created a remarkable foundation for growth. I am privileged to join the company at this pivotal stage and look forward to working with Vinod and our colleagues in shaping the next chapter-anchored in innovation, quality, and care that reaches patients globally.”

Plasmagen has steadily expanded its leadership team to support these ambitious growth plans, appointing Sethu Madhavan as COO (Manufacturing & Technical Operations) and Arnav Jain as CFO in 2025. With this strengthened management team, Plasmagen is confident of driving sustainable growth, expanding its market footprint and creating lasting value for patients and stakeholders alike.